Loading...
NPI 1497933162 · San Diego, CA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Millennium Health, LLC is a clinical medical laboratory provider located in San Diego, California. This profile covers 5 Medicare and 72 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Millennium Health, LLC |
| Address | 16981 Via Tazon |
| City | San Diego |
| State | CA |
| ZIP | 92127 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | February 5, 2008 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $579.3M |
| Medicare | $20.4M |
MILLENNIUM HEALTH, LLC is operating as a specialized Clinical Medical Laboratory focused on drug testing workflows: its Medicare top codes are dominated by definitive mass-spectrometry confirmatory tests (G0482, G0483, G0481) and high-volume presumptive screens (80307), which is consistent with a laboratory model that performs large-scale screening and confirmatory testing rather than point-of-care services. The Medicare code-level detail shows heavy use of definitive methods (GC/MS or LC/MS), indicating technical capacity for complex toxicology testing rather than basic chemistry panels.
Revenue concentration on Medicare is extreme: the precomputed top 3 codes by revenue account for 84.7% of this provider's total Medicare revenue, with G0482 ($7.6M, 37.2%), G0483 ($6.8M, 33.4%) and G0481 ($2.9M, 14.1%) comprising the bulk of billed Medicare dollars. Each of these Medicare codes is reported as an extreme outlier in national volume (100th percentile) with ranks at or near the top of national provider lists, underscoring that a small set of high-complexity codes drives most Medicare income.
On Medicaid the business concentration is similarly focused but on a much larger scale: the precomputed top 3 codes by revenue account for 67.1% of the provider's total Medicaid revenue, led by G0482 ($152.3M, 27.4%), G0483 ($130.1M, 23.4%) and 80307 ($91.2M, 16.4%). All three of those Medicaid codes rank #1 in-state and are labeled as extreme outliers (100th percentile), indicating that MILLENNIUM HEALTH is the dominant in-state biller for both definitive confirmatory testing and high-volume presumptive screens.
The payer mix is heavily skewed toward Medicaid in absolute scale: reported lifetime Medicaid revenue is $579.3M versus $20.4M in Medicare, making Medicaid the overwhelmingly larger revenue source for this provider. Given those totals, the enterprise should be considered effectively Medicaid-focused by revenue while still maintaining nationally notable Medicare volumes for select toxicology codes.
Competitive standing differs by payer: nationally, MILLENNIUM HEALTH ranks in the 99–100th percentile and is described as an extreme outlier for multiple Medicare toxicology codes (e.g., G0482 ranks #2 of 1618, G0483 ranks #3 of 1063, G0481 ranks #3 of 1766), which characterizes it as a major national volume player for these specialized tests even though overall Medicare revenue is modest compared with Medicaid. In California Medicaid, the provider is clearly the market leader for drug-testing codes (multiple #1 ranks in-state at the 100th percentile), signaling dominant state-level share for both confirmatory and screening tests.
Operational scale is evident from claim volumes in Medicaid: G0482 shows 1.8M claims, G0483 shows 993K claims and 80307 shows 2.9M claims in Medicaid data, which—paired with the large dollar amounts reported—indicates a centralized, high-throughput testing operation that likely handles very large specimen volumes and wide referral networks. Those same patterns on Medicare (tens of thousands of claims for G0482, G0483, G0481 and 80307) suggest the lab executes high-volume workflows across both payers, with Medicaid volumes substantially larger.
Tenure and market presence are long-standing: the NPI was enumerated on 2008-02-05 (~18 years ago), supporting that this is an established laboratory with sustained operational history in the California market and national relationships for selected Medicare toxicology testing lines. The combination of long tenure and extreme-volume rankings implies entrenched capacity and likely significant lab infrastructure to support confirmatory mass-spectrometry testing at scale.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 39,200 | $190 | $7.6M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 28,290 | $240 | $6.8M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 18,790 | $150 | $2.9M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 32,080 | $60 | $2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10,510 | $110 | $1.2M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
72 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,813,370 | $80 | $152.3M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 993,030 | $130 | $130.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,943,170 | $30 | $91.2M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,093,440 | $70 | $76.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 898,070 | $50 | $43.1M |
| 80321 | The lab analyst detects and measures the alcohol biomarker in a patient specimen. Alcohol biomarkers are physiological indicators of the alcohol exposure or ingestion. In this test, the analyst tests… | 865,210 | $10 | $4.3M |
| 83992 | The lab analyst measures the level of this drug, phencyclidine, typically in a urine or blood sample. This very potent street drug is a common drug of abuse. | 648,610 | $10 | $3.9M |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 964,260 | $1 | $3.9M |
| 80365 | The lab analyst measures the amount of or detects the presence of oxycodone, a synthetic opioid pain medication, in a patient specimen. | 962,040 | $1 | $3.8M |
| 80354 | The lab analyst measures the amount of or detects the presence of fentanyl in the patient specimen. | 957,690 | $1 | $3.8M |
Showing 1–10 of 72
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
72 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 370 | $80 | $4.1M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 100 | 520 | $120 | $2.4M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 70 | 650 | $70 | $1.6M |
| 81479 | Use 81479 to report a molecular pathology procedure that does not have a specific code. | 4 | 50 | 500 | $160 | $1.1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1 | 660 | 1,490 | $30 | $417.2K |
| 80352 | The lab analyst measures the amount of or detects the presence of seven or more synthetic cannabinoids present in the patient specimen. | 1 | 10 | 50 | $1 | $355.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 340 | 970 | $40 | $343.6K |
| 80363 | The lab analyst measures the amount of or detects the presence of three or four opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 1 | 10 | 100 | $1 | $342.6K |
| 80323 | The lab analyst identifies and evaluates the level of alkaloid drugs in a patient specimen that are not specified elsewhere in CPT® by a different code from the class of alkaloids. | 1 | 10 | 440 | $10 | $328.2K |
| 80321 | The lab analyst detects and measures the alcohol biomarker in a patient specimen. Alcohol biomarkers are physiological indicators of the alcohol exposure or ingestion. In this test, the analyst tests… | 1 | 20 | 290 | $10 | $304.6K |
Showing 1–10 of 72
Other providers in the same ZIP code as Millennium Health, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Joel Lamon | CA | Hematology & Oncology Physician | $1.3M | $0 |
| Anne Truitt | CA | Dermatology Physician | $550.6K | $0 |
| Sharp Healthcare | CA | Clinical Medical Laboratory | $440.3K | $530 |
| Bhargavbhai Patel | CA | Internal Medicine Physician | $188.8K | $7.6K |
| Ling Merkes | CA | Occupational Therapist | $27.8K | $0 |
| Sheri Smith | CA | Speech-Language Pathologist | $2.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.